Since
our inception in 1993, AnaSpec has assisted scientists in the design and synthesis
of >50,000 peptides. As a result, our combined knowledge and expertise provide
premium solutions to our customers.
AnaSpec routinely completes difficult peptide synthesis such as synthesis of
long peptides (>90-mers), peptides containing unusual modifications, and
cyclic peptides. In addition, we have the capacity for large-scale synthesis
(>100 g).
Optimized
Fmoc and Boc methodologies are employed for peptide syntheses. Cleavage of peptides
is performed using trifluoroacetic acid (TFA), hydrogen fluoride (HF), or other
appropriate methods. Most of the peptides are purified by HPLC using reverse
phase C4 and C18 columns. Alternative purification methods (e.g., ion exchange
and gel filtration chromatography) are used when needed. AnaSpec is equipped
with state-of-the-art automated peptide synthesizers capable of performing synthesis
ranging from small (0.025 mmol) to large (50 mmol) scale. These state-of-the-art
synthesizers, coupled with our experienced peptide chemists, enable us to deliver
our peptides quickly and in high quality (purity of 90-95% is typical). Most
custom orders can be expected to be delivered in two to three weeks. Complete
confidentiality of all orders is assured.
AnaSpec’s synthesis facilities located in Fremont, California means that we
are able to provide comprehensive oversight of the entire peptide synthesis
process. This ensures that we consistently meet our customer’s product specifications.
All custom peptides are accompanied with MS and HPLC analyses. Additional analytical
data (e.g., amino acid analysis, sequencing) are available upon request. AnaSpec
is also proud to be certified to ISO 9001:2008.
Custom
Peptide Modifications
| • Alkyne peptides
• Azide peptides
• BSA, KLH conjugated peptides for antibody production |
| |
| • C-terminal modifications |
| |
* Aldehydes |
|
| |
* Alcohols |
|
| |
* Chloromethyl Ketones |
|
| |
* Cysteamide |
|
| |
* Ester |
|
| |
* N-Alkyl Amides |
|
| |
* Hydrazides |
|
| |
* Thio ester |
|
| • Cyclic peptides |
|
| |
* N->C |
|
| |
* Disulfide (S-S bond formation) |
|
| • Dehydro peptides |
|
| |
* dehydroalanine; dehydroleucine, dehydroproline |
|
| • Dityrosine Cross linked peptides |
|
| • Drug-peptide conjugates |
|
| • Dye-labeled peptides: |
|
| |
* C-terminal |
|
| |
* AFC, AMC, Dap(Dnp), Lys(Dye), pNA, Rh110 |
|
| |
* N-terminal |
|
| |
* HiLyte Flour™ dyes (405, 488, 555, 647, 680, 750) |
|
| |
* QXL™ quenchers |
|
| |
* FAM, FITC, MCA, Rox, Sulforhodamine 101, TAMRA |
|
| • FRET Substrates |
|
| |
* 5-FAM/QXL™ 520 |
|
| |
* HiLyte Fluor™ 488/QXL™ 520 |
|
| |
* TAMRA/QXL™ 570 |
|
| |
* EDANS/DABCYL and other FRET pairs |
|
| • Glycopeptides |
|
| • Heavy Isotope Labeled Peptides (ClearPoint peptides labeled
with D, C13, N15) |
|
| • Hydrocarbon Stapled Peptides |
|
| • Lactam peptides |
|
| • Lipopeptides |
|
| |
* Prenylated |
|
| |
* Farnesyl |
|
| |
* GeranylGeranyl |
|
| • MAPS (Multiple Antigenic Peptide) |
|
| • Methylated peptides |
|
| |
* Lys(Me), Lys(Me)2, Lys(Me)3, Arg(Me)2 symmetrical, Arg(Me)2
assymmetrical |
|
| |
* Na-Methylated |
|
| |
* Ca-Methylated |
|
| • N-terminal Modifications |
|
| |
* Acetylated |
|
| |
* Biotinylated |
|
| |
* Bromoacetylated |
|
| |
* DOTA |
|
| |
* Formylated |
|
| |
* Myristoylated |
|
| |
* Succinylated |
|
| • Pegylated peptides |
|
| • Peptide libraries |
|
| |
* 96-well plate libraries |
|
| |
* One-Bead One-Peptide |
|
| • Peptidomimetics |
|
| • Peptide bond modifications |
|
| |
* Ester (Depsipeptides) |
|
| |
* Amine (reduced amide bond) |
|
| • Phosphopeptides |
|
| |
* Phosphoserine, Phosphothreonine, Phosphotyrosine |
|
| • Sulfated Tyrosine or Serine |
|
| • Thiolactone peptide |
|
| • TR-FRET Substrates |
|
| |
* Europium/QXL™ 610 |
|
| |
* Europium/HiLyte Fluor™ 647 |
|
| • Unusual Synthesis |
|
| |
|
|
For
additional information about our custom peptide synthesis services, please contact
service@anaspec.com
For online custom peptide synthesis quote request, please click
here, or contact quotes@anaspec.com.
|